Manchester Cancer Research Centre shared a post on LinkedIn:
“Transforming melanoma treatment in Manchester.
Melanoma is the 5th most common cancer in the UK, but researchers in Manchester are transforming our understanding and treatment of the disease.
The CAcTUS clinical trial at The Christie NHS Foundation Trust is investigating how circulating tumour DNA (ctDNA) can be used to personalise treatment options for patients with advanced melanoma. By identifying the best time to switch between targeted therapy and immunotherapy, the trial hopes to improve patient outcomes and help optimise treatment strategies.
Learn more about the future of melanoma research in Manchester.
Click here to watch the video.”